Navigation Links
Mylan Applauds Obama Administration's Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
Date:11/9/2011

PITTSBURGH, Nov. 9, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today applauded the Obama administration's call to action in the global fight against HIV/AIDS.

Mylan President Heather Bresch commented: "While the generics industry has made significant contributions toward making HIV/AIDS medicines more affordable, we believe the focus must now turn to expanding access to treatment for more people. As such, we're heartened that the Obama administration is embracing treatment as prevention and rallying global leaders to help end the global HIV/AIDS pandemic by making the creation of an 'AIDS-free generation' a policy priority. Achieving these objectives, as well as the goal of universal access set forth by the United Nations, will require close cooperation between governments, non-governmental organizations and the private sector."

Yesterday's speech by Secretary of State Hillary Clinton at the National Institutes of Health (NIH) comes at a critical time. Despite significant success in lowering infection rates, HIV/AIDS remains a leading cause of death globally and there are 7,000(1) new infections every day. Less than half of the estimated 15 million(2) people needing treatment receive it.

Recent scientific studies, including those conducted by NIH and the National Institute of Allergy and Infectious Diseases (NIAID), underscore the importance of early treatment. Evidence from these studies suggests that earlier initiation of treatment following testing and diagnosis may be the most effective means to prevent HIV transmission.

"With the 2012 International AIDS Society Conference taking place here in the U.S. in July 2012, the Obama administration has an ideal platform to take further steps to deliver on its commitments to addressing the global AIDS pandemic and make an 'AIDS-free generation' a reality. Mylan intends to do all it can to help by partnering with the administration, the U.N. and others to continue to expand access to high quality, affordable antiretrovirals used in the treatment of HIV/AIDS," concluded Bresch.

Approximately one-third of people in the developing world being treated for HIV/AIDS depend on a Mylan antiretroviral (ARV) product.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

(1) United Nations Program on HIV/AIDS
(2) World Health Organization


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan to Acquire Pfizer Respiratory Delivery Platform
2. Mylan Receives Approval for Generic Version of MS Contin® Tablets
3. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
4. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
5. Matrix Laboratories Completes Name Change to Mylan Laboratories
6. Mylan Announces Femcon® Fe Settlement Agreement
7. Mylan Announces Intention to Refinance Existing Secured Credit Facility
8. Mylan Comments on Death of Company Co-Founder and Former Chairman and CEO Milan "Mike" Puskar
9. Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
10. Mylan Announces XELODA® Settlement and License Agreement
11. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... for the fourth quarter and year ended December 31, ... of transformational progress for Orexigen, beginning with the re-acquisition ... Commencing early March, the team at Orexigen demonstrated remarkable ... which reshaped and strengthened our Company while rewarding us ...
(Date:3/28/2017)... BOSTON , March 28, 2017  Market ... today announced a partnership with premium news content ... pharmaceutical companies to extract key insights from Dow ... mining technology. The Linguamatics I2E platform ... 20 global pharmaceutical companies. The Linguamatics-Dow Jones partnership ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul ... , WHAT: , Medical doctors and PhD scientists will speak to the press on ... Trump in support of an independent vaccine safety commission. , WHERE: , Zenger ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business Management Association (RBMA) ... as its new executive director. Mr. Still was selected through a careful months-long search ... as he is known to our members, has been a part of building the ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... physicians, Paul Yost, will begin serving as new board chair for Orange County ... Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... MA (PRWEB) , ... March 28, 2017 , ... ... for direct measurement of corrosive ions found in power plant water and steam. ... components such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. ...
Breaking Medicine News(10 mins):